CHKP
Check Point Software Technologies Ltd.
CHKP's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over CHKP overall, supported by stronger modeled upside and stronger fundamentals.
CHKP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
CHKP's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CHKP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $147 | — |
| Current | 15x | $147 | — |
| Cheap | 19x | $187 | +26% |
| Fair | 21x | $203 | +38% |
| Expensive | 25x | $241 | +64% |
Historical ranges are pointers, not guarantees.
CHKP's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over CHKP in the historical PE scenario, which offers more potential upside but is not a forecast.
CHKP Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect CHKP's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CHKP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.74 | +10% |
| Q2 2026 | $9.73 | +27% |
| Q1 2026 | $9.70 | +28% |
| Q4 2025 | $9.60 | +29% |
| Q3 2025 | $9.13 | +25% |
| Q2 2025 | $7.68 | +6.1% |
| Q1 2025 | $7.58 | +5.4% |
| Q4 2024 | $7.47 | +5.1% |
| Q3 2024 | $7.32 | +2.2% |
CHKP's earnings per share have climbed steadily: $9.73 over the past year, up 27% from the year before, and higher year over year for 16 quarters in a row.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CHKP on earnings, with stronger typical year-over-year growth.
CHKP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $673.6M | +1.3% |
| Q1 2026 | $668.4M | +4.8% |
| Q4 2025 | $744.9M | +5.9% |
| Q3 2025 | $677.5M | +6.7% |
| Q2 2025 | $665.2M | +6% |
| Q1 2025 | $637.8M | +6.5% |
| Q4 2024 | $703.7M | +6.1% |
| Q3 2024 | $635.1M | +6.5% |
CHKP's revenue has grown year over year every quarter since late 2020: $674M last quarter, up 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 27% | -3.1 points |
| Q1 2026 | 28% | -3 points |
| Q4 2025 | 31% | -4.9 points |
| Q3 2025 | 29% | -5 points |
| Q2 2025 | 31% | -2.8 points |
| Q1 2025 | 31% | -1.7 points |
| Q4 2024 | 36% | -1.8 points |
| Q3 2024 | 34% | -3.5 points |
CHKP's operating margin was 27% last quarter, down 3.1 points from the same quarter a year ago, near the bottom of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CHKP on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CHKP on profitability, with a higher operating margin.
CHKP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $160.7M | -37% |
| Q1 2026 | $435.9M | +5.4% |
| Q4 2025 | $277.3M | +17% |
| Q3 2025 | $265.1M | +8.6% |
| Q2 2025 | $256M | +32% |
| Q1 2025 | $413.7M | +17% |
| Q4 2024 | $236.1M | +0.8% |
| Q3 2024 | $244.1M | +13% |
CHKP's free cash flow has been positive every quarter for seven years: $1.1B over the past year, about the same as the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CHKP on cash flow, with stronger typical year-over-year growth.
CHKP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.5% | -2.6M shares |
| 1 year | -6.3% | -6.9M shares |
| 3 years | -13% | -15.7M shares |
| 5 years | -23% | -31.3M shares |
| Available history | -31% | -47.3M shares |
CHKP has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $324.9M |
| Q1 2026 | $325M |
| Q4 2025 | $425M |
| Q3 2025 | $366.8M |
| Q2 2025 | $325M |
| Q1 2025 | $325M |
| Q4 2024 | $324.9M |
| Q3 2024 | $325M |
CHKP spent $1.4B buying back its own shares over the past year, up 11% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CHKP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
CHKP's net debt is about 1.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over CHKP on leverage, with a lower net debt burden relative to earnings.
CHKP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 62.8 | Neutral |
CHKP's weekly RSI is 55 (neutral) and its Stochastic is 63 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CHKP PE vs Technology Sector
| Metric | CHKP | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 46% below |
| PE % | 8 | 35 | 27 pts below |
CHKP has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CHKP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $142.4 | 3.6% above |
| 20 week MA | $136.6 | 8% above |
| 50 week MA | $147.6 | 0.1% below |
| 100 week MA | $177.1 | 17% below |
| 200 week MA | $164.5 | 10% below |
CHKP has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CHKP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $111.8 | $134.8 | +21% |
| 2021 | $134.8 | $114.9 | -15% |
| 2022 | $114.9 | $127.0 | +11% |
| 2023 | $127.0 | $152.8 | +20% |
| 2024 | $152.8 | $187.9 | +23% |
| 2025 | $187.9 | $189.6 | +0.9% |
| 2026 YTD | $189.6 | $147.5 | -22% |
CHKP has finished higher in five of the last six years. It's down 22% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over CHKP on returns for 2026, with the stronger performance.